Trimurthi , a pharmaceutical company, has made significant corporate decisions that may interest investors and market watchers. The company's Board of Directors approved two key actions on October 23, 2025, as disclosed in their recent filing.

Board Appointment

The company has appointed Ms. Sridevi Belide as an Additional Non-Executive Non-Independent Director. Ms. Belide, who holds an MBBS degree, brings her medical expertise to the board. She is related to the company's promoter group.

Equity Share Allotment

The Board approved the allotment of 16,61,000 equity shares. Here are the key details of this allotment:

This allotment was made through the conversion of warrants, which were part of a larger issue of 1,50,00,000 warrants allotted on January 10, 2025. It's important to note that 45,30,000 warrants had already been converted prior to this allotment.

Impact on Share Capital

The equity share allotment has led to changes in the company's paid-up capital:

This increase in paid-up capital and the number of outstanding shares may have implications for the company's equity structure and potentially its market valuation.

Investors and market participants may want to consider how these corporate actions might affect Trimurthi's governance, capital structure, and future strategic directions.

Trimurthi has announced a significant partnership with GMBU e.V., a German research institution, to advance the large-scale production of Astaxanthin, a potent antioxidant with wide-ranging applications in the nutraceutical and pharmaceutical industries.

Key Partnership Details

• Agreement Type: Technology Transfer
• Partner: GMBU e.V., Halle (Saale), Germany
• Focus: Large-scale production of Astaxanthin
• Location: Novelix's laboratories at BTIC Park, Genome Valley, Hyderabad

Scope of Collaboration

Under this agreement, GMBU e.V. will transfer its proprietary technology and expertise for the cultivation and scale-up of Haematococcus pluvialis, the microalgae known for its high Astaxanthin content. Novelix will provide financial and infrastructural support, including:

• Algal strains
• Media components
• Laboratory equipment
• Infrastructure

Production Plans

Novelix plans to establish a GMP-certified production facility at its Techno Park site in Hyderabad to manufacture Astaxanthin in bulk. The company aims to target key markets across:

• Europe
• North America
• India

About Astaxanthin

Astaxanthin, derived from Haematococcus pluvialis, is recognized for its strong antioxidant properties and has shown promise in various health applications:

The compound is valued for its ability to preserve redox balance and mitochondrial function, potentially mitigating oxidative stress—a primary cause of chronic inflammation and degenerative diseases.

Leadership Perspectives

Dr. Enrico Ehrhardt, Head of the Department of Molecular Biology at GMBU e.V., commented on the partnership: "This is a significant milestone for GMBU e.V. as we partner with Novelix Pharmaceuticals Limited, a leading Indian pharmaceutical company, for the development and scale-up of Haematococcus pluvialis. We believe this collaboration will open new avenues for joint innovation across biotechnology and healthcare domains, ensuring affordable access to high-quality therapeutic products."

Mr. Gattu Gyan Prakash, Director of Novelix Pharmaceuticals Limited, expressed enthusiasm about the collaboration: "We are thrilled to collaborate with GMBU e.V., Germany, to bring Astaxanthin production to India. This compound has tremendous therapeutic potential and commercial promise as a nutraceutical. Beyond product development, this partnership symbolizes a robust Indo-German collaboration model in biotechnology and life sciences. Novelix remains committed to advancing transformative, affordable healthcare solutions—from novel drug discovery and medical diagnostics to therapeutics and biomedical devices."

This strategic partnership underscores Novelix Pharmaceuticals' commitment to innovation in the biopharmaceutical sector and its focus on developing high-quality, affordable healthcare solutions for global markets.